TELA — TELA Bio, Inc.

TELA Bio Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $19.1 million, up 3% from $18.5 million in Q1 2025.
• International Sales: $3.7 million, a 41% increase year-over-year, driven by the hernia portfolio.
• OviTex Revenue: $12.6 million, up from $12.1 million, with unit volume increasing 16% year-over-year (5.8 thousand units sold).
• Gross Profit: $12.5 million, maintaining a gross margin of 66%, down from 68% due to higher inventory charges.
• Operating Expenses: $23 million, flat compared to Q1 2025.
• Loss from Operations: $10.5 million, unchanged from the previous year.
• Net Loss: $12.3 million, compared to $11.3 million in Q1 2025, primarily due to increased interest expenses.
• Cash Position: $39.5 million in cash and cash equivalents.

2. Strategic Updates and Business Highlights

• Commercial Strategy Reset: TELA has fully staffed its US commercial team and is focused on executing its redefined strategy, which includes launching the OviTex long-term resorbable (LTR) portfolio.
• Product Launch: The OviTex LTR was launched on April 1, 2026, aimed at providing surgeons with a fully resorbable solution for hernia repair.
• European Growth: The company reported strong performance in Europe, particularly in the UK, with a 41% revenue growth driven by the hernia portfolio.
• Clinical Validation: Positive feedback from the NHS on OviTex's efficacy in reducing complications and costs, along with growing clinical evidence supporting its use.

3. Forward Guidance and Outlook

• 2026 Revenue Growth Guidance: TELA is reiterating its guidance for at least 8% revenue growth over 2025, with Q2 revenue expected to be approximately $20 million.
• Sales Force Productivity: Anticipation of improved productivity from the newly hired sales team, with expectations for significant revenue contributions in the second half of 2026.

4. Bad News, Challenges, or Points of Concern

• Decline in PRS Revenue: OviTex PRS revenue decreased slightly to $5.9 million due to the absence of high-volume implanters during Q1.
• Operating Loss: The company expects continued operating losses in the near term, although improvements are anticipated as revenue grows.
• Interest Expense: Increased interest expenses from a new credit facility are impacting net losses.
• Dependence on Key Implanters: The reliance on a small number of high-volume implanters poses a risk to revenue stability.

5. Notable Q&A Insights

• Guidance Philosophy: Management indicated that the first quarter was a transitional period with significant changes in strategy, but they remain confident in achieving their guidance due to early signs of productivity from new hires.
• Market Dynamics: Differences in the competitive landscape between the US and Europe were discussed, with Europe being more straightforward in terms of pricing and procurement processes.
• Sales Force Retention: Management expressed confidence in retaining the new sales team, attributing this to a streamlined hiring process and the company's innovative product pipeline.
• Clinical Evidence: The increasing adoption of OviTex by influential surgeons and the positive clinical data being published are seen as key drivers for future growth.

Overall, TELA Bio is positioned for growth in 2026, supported by a strong product portfolio and a newly structured commercial strategy, despite facing challenges related to revenue concentration and operating losses.